Macrolide

Macrolides are a class of antibiotics that exert their core biological function by inhibiting bacterial protein synthesis through interaction with the bacterial ribosome, thereby suppressing microbial growth[1][2]. Mechanistically, macrolides bind within the nascent peptide exit tunnel of the 50S ribosomal subunit and interfere with translation by preventing normal elongation of the growing peptide chain during protein biosynthesis[1][2][3]. This translational inhibition pathway is closely linked to interactions with 23S rRNA and ribosomal components that regulate peptide progression through the ribosome[2][3][4]. In disease settings, macrolides are widely used for bacterial infections and have also demonstrated anti-inflammatory and immunomodulatory activities that contribute to their application in chronic respiratory disorders, including chronic obstructive pulmonary disease and non-cystic fibrosis bronchiectasis[4][5]. Compared with other ribosome-targeting antibiotic classes, macrolides are distinguished by their binding site within the 50S subunit and their ability to selectively affect protein synthesis through obstruction of the peptide exit tunnel[2][3]. Research on related compounds has further shown that structural modification of the macrolide scaffold can generate derivatives with activity against macrolide-resistant bacteria, providing useful experimental tools for investigating resistance mechanisms and ribosome function[5][6]. Therefore, macrolides remain important molecular probes for studying translation regulation, antibiotic resistance, and host inflammatory responses in infection-related experimental models[1][4][6].